Table 1.

Objective response and DOR in patients with gBRCA-mutated advanced ovarian cancer who received three or more prior lines of chemotherapy in Study 42

N = 137
Objective response rate (95% CI)34% (26–42)
Complete response2%
Partial response32%
Median DOR in months (95% CI)7.9 (5.6–9.6)